Meet an Unreasonable Venture
CyanoCapture
Bringing affordable carbon capture to emitting industries worldwide.
CyanoCapture is using a genetically engineered microbe to make CO2 low-cost for emission sites. The company currently holds patents on the world’s fastest photosynthetic organism for CO₂ fixation and has developed methods to convert CO₂ into battery graphite and high-value compounds for biopharma. In December 2024, CyanoCapture created a strain that can make recombinant insulin out of CO2, paving the way for low-cost carbon-negative biomanufacturing to be possible.
Notable Achievements
- Raised $4.49M in equity financing from VCs and angels and a further $5M in non-dilutive prizes.
- Secured a 12-month partnership with L’Oréal (2025).
- First company in the world to successfully turn CO2 into insulin using photosynthesis.
Currently Operating in One Region
Get the Unreasonable Newsletter
Get monthly updates on CyanoCapture and all of the other ventures working to solve the world's toughest problems.